Eleclazine (GS-6615) is primarily investigated for its potential in treating cardiac arrhythmias, particularly long QT syndrome (LQTS). It functions as a late sodium current inhibitor, which helps stabilize the electrical activity of the heart and reduces the risk of abnormal heart rhythms. This makes it a promising candidate for managing conditions where excessive sodium influx contributes to arrhythmias. Additionally, its mechanism of action is being explored for broader applications in other heart rhythm disorders, offering a potential therapeutic option for patients with limited treatment alternatives. Research continues to evaluate its efficacy and safety in clinical settings.